Indication
Eye Disorders
29 clinical trials
33 products
Product
MCO-010Clinical trial
A Phase 2b Randomized, Double-Masked, Sham-Controlled, Study to Evaluate the Efficacy and Safety of Intravitreal Injection of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]Status: Completed, Estimated PCD: 2023-02-27
Clinical trial
Long Term Follow-up for Subjects Who Previously Participated in the NTXMCO-002 RESTORE StudyStatus: , Estimated PCD: 2027-07-01
Clinical trial
FOCUS: An Open Label First in Human Phase I/II Multicentre Study to Evaluate the Safety, Dose Response and Efficacy of GT005 Administered as a Single Subretinal Injection in Subjects With Macular Atrophy Due to AMDStatus: Active (not recruiting), Estimated PCD: 2024-06-28
Product
GT005Clinical trial
Screening And Detecting Eye Diseases With Hybrid Deep Learning Algorithms From Fundus Images And Validation Of Automated Artificial Intelligence AlgorithmStatus: Recruiting, Estimated PCD: 2024-03-01
Product
Mydriatic AgentProduct
Eyecyte-RPE™Clinical trial
A Phase 1/2a Multi-Center, Dose-Escalation Study to Evaluate the Safety & Efficacy of Eyecyte-RPE™ When Administered as a Single-dose Subretinal Injection in Subjects With Geographic Atrophy Secondary to Dry Age-related Macular DegenerationStatus: Not yet recruiting, Estimated PCD: 2024-10-01
Product
OTX-DEDClinical trial
A Randomized, Double-masked, Study to Evaluate the Efficacy and Safety of OTX-DED (Dexamethasone Intracanalicular Ophthalmic Insert) for the Short-term Treatment of the Symptoms of Dry Eye Disease (DED)Status: Active (not recruiting), Estimated PCD: 2024-04-11
Product
Controlled InsertionProduct
Collagen Punctal PlugProduct
AAV OPTIRPE65Clinical trial
Long-term Follow-up Study of Participants Following an Open Label, Multi-centre, Phase I/II Dose Escalation Trial of an Adeno-associated Virus Vector (AAV2/5-OPTIRPE65) for Gene Therapy of Adults and Children With Retinal Dystrophy Owing to Defects in RPE65 (LCA2)Status: Completed, Estimated PCD: 2023-07-01
Clinical trial
Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Efficacy of EDIT-101 in Adult and Pediatric Participants With Leber Congenital Amaurosis Type 10 (LCA10), With Centrosomal Protein 290 (CEP290)-Related Retinal Degeneration Caused by a Compound Heterozygous or Homozygous Mutation Involving c.2991+1655A>G in Intron 26 (IVS26) of the CEP290 Gene ("LCA10-IVS26")Status: Active (not recruiting), Estimated PCD: 2025-05-23
Clinical trial
A Phase 2, Proof-of-Concept, Randomized, Double-Masked, Placebo-Controlled Study to Determine the Efficacy and Safety of LASN01 in Patients With Thyroid Eye DiseaseStatus: Recruiting, Estimated PCD: 2025-03-01
Product
LASN01Product
PlaceboProduct
IVB102Clinical trial
An Open-label, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IVB102 Injection in Subjects With X-linked Retinoschisis (XLRS)Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase 2b, Randomized, Double-Mask, Placebo-Controlled, Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)Status: Recruiting, Estimated PCD: 2023-07-01
Product
LinsitinibProduct
linsitinibClinical trial
A Multicenter, Extension Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)Status: Recruiting, Estimated PCD: 2026-06-01
Product
EDIT-101Clinical trial
A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety and Tolerability of Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene (Sirius)Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
QR-421aClinical trial
A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety and Tolerability of QR-421a in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision LossStatus: Terminated, Estimated PCD: 2022-08-02
Product
Aceclidine + BrimonidineClinical trial
A Multi-Center, Randomized, Double-Masked, Placebo-Controlled Phase 3 Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Treatment of PresbyopiaStatus: Recruiting, Estimated PCD: 2024-07-31
Product
UltevursenProduct
AceclidineClinical trial
A Placebo-Controlled, Double-masked Phase-1 Study in Healthy Subjects Investigating the Safety and Tolerability of Laquinimod Eye DropsStatus: Completed, Estimated PCD: 2023-01-19
Product
LaquinimodClinical trial
An Open-Label, Extension Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of QR-110 in Subjects With Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 GeneStatus: Terminated, Estimated PCD: 2022-10-03
Product
QR-110Clinical trial
Safety Study: A Multi-Center, Double-Masked Phase 3 Safety Study Evaluation of the Long-Term Safety of LNZ101 in Presbyopic SubjectsStatus: Completed, Estimated PCD: 2024-02-09
Clinical trial
A Multi-Center, Double-Masked Phase 3 Evaluation of the Safety and Efficacy of LNZ101 for the Treatment of PresbyopiaStatus: Completed, Estimated PCD: 2023-12-14
Product
VehicleClinical trial
FLuorometholone as Adjunctive MEdical Therapy for TT Surgery (FLAME) TrialStatus: Active (not recruiting), Estimated PCD: 2024-11-30
Product
FluorometholoneProduct
Artificial TearsClinical trial
Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial KeratitisStatus: Recruiting, Estimated PCD: 2024-10-01
Product
ASOClinical trial
Comparison of Efficacy and Safety of Mitomycin and Aflibercept Used to Support Primary Trabeculectomy - a Prospective, Randomized Trial in Patients With Open-angle Glaucoma Undergoing Surgery.Status: Completed, Estimated PCD: 2019-07-31
Product
AfliberceptProduct
MitomycinClinical trial
Vitrectomy, Subretinal Tissue Plasminogen Activator and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative Age-Related Macular Degeneration (TIGER): a Phase 3, Pan-European, Two-group, Observer-masked, Superiority, Randomised Controlled Surgical Trial.Status: Recruiting, Estimated PCD: 2025-01-01
Product
recombinant TPA (Alteplase)Clinical trial
Abatacept in Patients With Birdshot HLA A29 Uveitis: A Phase II Prospective 0pen Label Interventional Proof-of-Concept StudyStatus: Completed, Estimated PCD: 2022-01-01
Product
AbataceptClinical trial
A Prospective, Single-Center, Open-Label, Study of the Plasma Pharmacokinetics and Safety Following Topical Administration of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With PresbyopiaStatus: Completed, Estimated PCD: 2023-10-03
Clinical trial
A Multi-Center, Double-Masked Phase 3 Evaluation of the Safety and Efficacy of LNZ101 for the Treatment of PresbyopiaStatus: Completed, Estimated PCD: 2023-12-15
Product
BrimonidineClinical trial
A Phase 2b, Prospective, Multicenter, Randomized, Double-Masked, Active-Controlled Study to Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With Diabetic Macular EdemaStatus: Recruiting, Estimated PCD: 2025-03-01
Product
foselutoclaxProduct
Uveitis Inducing DrugsClinical trial
A Phase 1 Open-Label, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of Intravitreally Administered VP-001 in Participants With Confirmed PRPF31 Mutation-Associated Retinal DystrophyStatus: Not yet recruiting, Estimated PCD: 2025-11-01
Product
VP-001